Can I read 814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC) on EtoBox?

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC) by Y. Drew; R.T. Penson; D.M. O'Malley; J-W. Kim; S. Zimmermann; P. Roxburgh; J. Sohn; S.M. Stemmer; S. Bastian; M. Ferguson; B. You; S. Domchek; H. Gao; H. Angell; K. Meyer; L. Opincar; L. Ottesen; D.O. Koralek; S. Banerjee is a Medicine article available to read on EtoBox.

What is 814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC) about?

Background: SOLO2 (ENGOT Ov-21; NCT01874353) demonstrated that maintenance olaparib (O) in patients (pts) with platinum-sensitive relapsed EOC and a BRCA1/2 mutation led to clinically significant survival benefit. We report on the efficacy of subsequent chemotherapy at the time of disease progression. Methods: First subsequent treatment was analysed in pts who progressed according to RECIST1.1 in the O and placebo (P) arms. We conducted a post-hoc analysis of time to second progression (TTSP) calculated from the date of RECIST progression after O maintenance to next progression or death as a surrogate of first post-olaparib treatment progression-free survival. Results: 106/195 (54%) and 80/99 (81%) pts had a RECIST progression in the O and P arms respectively. Pt baseline demographics were balanced between both arms. Overall, 161/186 (87%) pts received a first subsequent therapy, including a chemotherapy in 150/161 (93%) and a PARP inhibitor in 29/161 (18%, all in the P arm). In the P arm, 33/75 (44%) and 42/75 (56%) pts received a non-platinum and a platinumbased chemotherapy respectively vs 32/86 (37%) and 54/86 (63%) in the O arm. Overall, in pts receiving subsequent treatment,

Who reads 814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)?

Author

Y. Drew; R.T. Penson; D.M. O'Malley; J-W. Kim; S. Zimmermann; P. Roxburgh; J. Sohn; S.M. Stemmer; S. Bastian; M. Ferguson; B. You; S. Domchek; H. Gao; H. Angell; K. Meyer; L. Opincar; L. Ottesen; D.O. Koralek; S. Banerjee

Publisher

Oxford University Press; Elsevier BV (ISSN 0923-7534)

Published

2020

Language

EN

Field

Medicine (Health Sciences)